For instance, CCR2/CCR5 inhibitors, such as PF-04136309 in pancreatic cancer, could disrupt TAM/Treg recruitment in ESCA, while CXCL8/CXCR2 blockade, trialed in CRC, may reduce MDSC/NET-mediated immunosuppression. Here, CXCR2 is linked to pancreatic neoplasm.